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Individuals with melanocortin 1 receptor (MC1R) gene variants have been shown to carry an increased risk for
the development of melanoma. In this study, we investigated the relationship of MC1R gene variants and the
risk of melanoma in 123 melanoma patients and 155 control subjects from Greece. The entire MC1R gene was
sequenced for polymorphisms and the results were correlated with host factors and pigmentary characteristics.
MC1R polymorphisms were present in 59.4% of melanoma patients compared to 37.5% of controls, yielding an
odds ratio (OR) of 2.43 (95% confidence interval (CI)¼ 1.50–3.96, Po0.001) for melanoma among MC1R carriers.
The risk of melanoma was enhanced in individuals carrying multiple variant alleles (OR¼ 6.97; 95%
CI¼ 1.86–26.12, P¼ 0.004). Only the Val60Leu, Arg142His, and Arg151Cys variants were significantly associated
with melanoma risk. In stratified analysis, the risk of melanoma among MC1R carriers was not influenced by
skin phototype, skin color, or hair color. No association was found between MC1R genotype and the age of
onset of melanoma, the tumor location, or the tumor thickness. In conclusion, MC1R polymorphisms are a
predisposing factor of melanoma in a southern European population with a relatively low incidence of the
disease.
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INTRODUCTION
The incidence and mortality rates of melanoma have been
increasing steadily in Caucasian individuals worldwide
(Parkin et al., 2003; de Vries and Coebergh, 2004).
Epidemiologic observations suggest that melanoma arises
from a complex interplay between environmental and
phenotypical features (Bliss et al., 1995; Breitbart et al.,
1997), which possibly occurs through distinct biological
pathways (Whiteman et al., 2003). With exposure to UVR
being so far the strongest environmental culprit (Katsambas
and Nicolaidou, 1996; Elwood and Jopson, 1997), several
phenotypic factors have been strongly associated with the
risk of melanoma, such as fair skin complexion, multiple
nevomelanocytic nevi, and the presence of clinically atypical
nevi (Garbe et al., 1994; Gandini et al., 2005). Genetic
factors are also involved in the pathogenesis of the disease, as
evidenced by the presence of germline mutations of the
CDKN2A and CDK4 genes in 30–40% of melanoma kinreds
(Kamb et al., 1994; Tsai and Tsao, 2004). In addition to these
genetic alterations, a number of low-penetrance genes have
been implicated in the genetic susceptibility to melanoma.
One of these genes is the melanocortin receptor-1 (MC1R)
gene that is located on chromosome 16q24.3 and encodes for
a G-protein-coupled receptor of 317 amino acids. The MC1R
is expressed in a variety of cells, including melanocytes and
keratinocytes, and functions as a receptor for a-melanocyte-
stimulating hormone and ACTH. Binding of a-melanocyte-
stimulating hormone with MC1R activates the intracellular
cAMP pathway and, through a series of downstream events
involving the transcription of tyrosinase gene, leads to the
production of the brown/black eumelanin (Schaffer and
Bologna, 2001). Variations or polymorphisms of the MC1R
gene may result in decreased receptor function, either at the
level of a-melanocyte-stimulating hormone binding or at the
level of cAMP signaling, resulting in a quantitative shift of
melanin synthesis from eumelanin to the red–yellow and
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potentially mutagenic pheomelanin (Valverde et al., 1995;
Box et al., 1997; Sturm et al., 2001). The effect of MC1R on
the different melanin classes has been shown convincingly in
mice (Lamoreux et al., 2001) and in human hair (Naysmith
et al., 2004), but remains debatable with regard to human
skin color (Hennessy et al., 2005).
More than 77 human alleles of the MC1R gene, with non-
synonymous changes, have been identified to date (Wong
and Rees, 2005). Three variants (Arg151Cys, Arg160Trp, and
Asp294His), in particular have been defined as ‘‘red hair
color’’ variants based not only on their diminished receptor
function in vitro, but also on their significant association with
specific phenotypic features, such as red hair, fair skin, and
freckling (Flanagan et al., 2000; Bastiaens et al., 2001a; Duffy
et al., 2004). Other alleles, such as Val60Leu, 86insA,
Asp84Glu, Arg142His, Arg151Cys, Ile155Thr, and His260-
Pro, have been statistically considered as full or partial ‘‘red
hair color’’ causing variants, based on genetic association
and family studies (Sturm, 2002). MC1R polymorphisms have
also been associated with sun sensitivity in individuals
without red hair (Healy et al., 2000; Rees, 2004), and with
an elevated risk of melanoma and non-melanoma skin cancer
(Valverde et al., 1996; Ichii-Jones et al., 1999; Palmer et al.,
2000; Box et al., 2001a; van Der Velden et al., 2001;
Kennedy et al., 2001; Bastiaens et al., 2001b). In the case of
melanoma, MC1R variants have been shown to act as a
modifier of melanoma risk in melanoma-prone families
carrying CDKN2A mutations (Box et al., 2001b; van Der
Velden et al., 2001).
Several of the studies examining the association of MC1R
variants with melanoma risk have been performed in
populations of Celtic origin. The association was also shown
to exist in two case–control studies from France (Matichard
et al., 2004) and northeastern Italy (Landi et al., 2005).
Although the epidemiologic factors underlying the risk of
melanoma in southern Europe do not vary significantly from
those in populations of northern latitudes (Naldi et al., 2000;
Landi et al., 2001; Lasithiotakis et al., 2004), the study of a
pigmentation gene, such as MC1R, in a mediterranean
country, with a higher proportion of relatively darker skinned
individuals, prompted us to conduct a case–control study in
the Greek population. Greece is reported to have the lowest
incidence of melanoma among European countries, with an
estimated age-standardized incidence rate of 3.35 cases per
100,000 inhabitants (Ferlay et al., 1999). In this study we
aimed (1) to determine the prevalence, type, and distribution
of MC1R variants among cases and controls, (2) to examine
the association of MC1R with the risk of melanoma, as well
as with other pigmentary characteristics, and (3) to investigate
a possible association between the presence of MC1R
variants and the age of onset, anatomic distribution, and
tumor thickness in melanoma cases.
RESULTS
Clinical and epidemiological risk factors of melanoma
The demographic and phenotypical characteristics in mela-
noma cases and controls are presented in Table 1. A younger
mean age was observed in the control subjects compared to
the examined melanoma patients (43.7 vs 53.0 years,
Po0.001). Fair skin was encountered more frequently in
melanoma cases (55.4 vs 41.4%, P¼ 0.004). The two groups
did not differ statistically significantly in terms of skin
phototype, hair color, and eye color.
Frequency of MC1R variants and association with pigmentary
characteristics
Overall, 18 different MC1R variant alleles were identified in
47.2% of 278 subjects (cases and controls), including 12 non-
synonymous and six synonymous changes (Table 2). The
most common variant was Val60Leu (36.6% in cases and
20% in controls). Among the major function variants, we
detected the Arg142His, Arg151Cys, and Arg160Trp alleles,
but not the Asp84Glu and Asp294His variants. All variants
comprised of amino-acid substitutions, and no deletions or
insertions were detected.
Table 1. Demographic characteristics and pigmentary
phenotype of melanoma cases and control subjects
Melanoma (N=123) Controls (N=155) P
Gender, n (%) 0.622
Male 63 (51.2) 84 (54.2)
Female 60 (48.8) 71 (45.8)
Age (years) o0.001
Mean (SD) 53.0 (15.4) 43.7 (15.2)
Phototype, n (%) 0.584
I 6 (5.3) 7 (4.6)
II 51 (45.1) 57 (37.5)
III 34 (30.1) 56 (36.8)
IV 22 (19.5) 32 (21.1)
Eye color, n (%) 0.079
Gray 4 (3.6) 0 (0.0)
Blue 19 (17.0) 25 (16.5)
Green 26 (23.2) 26 (17.1)
Light brown 29 (25.9) 40 (26.3)
Dark brown 34 (30.3) 61 (40.1)
Hair color, n (%) 0.727
Blonde 12 (10.7) 15 (9.9)
Red 3 (2.7) 5 (3.3)
Light brown 33 (29.5) 40 (26.3)
Dark brown 50 (44.6) 79 (52.0)
Black 14 (12.5) 13 (8.5)
Skin color, n (%) 0.004
White 62 (55.4) 63 (41.4)
Light brown 47 (41.9) 69 (45.4)
Dark 3 (2.7) 20 (13.2)
SD, standard deviation.
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The presence of an association between MC1R variants
alleles and pigmentary phenotype was examined using
subjects from the control group (Table 3). The presence of
MC1R variants was associated with hair color (Po0.001), but
not with skin color (P¼ 0.297) or skin phototype (P¼0.158).
The major function variants were more frequently encoun-
tered among red-haired individuals (60%) and among
individuals with skin type I (28%). No association was
identified between MC1R variants and eye color (P¼0.956).
Association of MC1R variants with melanoma risk
MC1R variants were much more common in the melanoma
group, with 59.4% carrying at least one variant, compared
with 37.5% of control subjects (Po0.001) (Table 4). In
addition, the presence of two or more MC1R polymorphisms
was found more frequently in melanoma cases (8.9%) than in
controls (2.0%). The presence of MC1R polymorphisms
conferred an almost two-fold increase of melanoma risk
relative to wild-type homozygotes (odds ratio (OR)¼2.43;
95% confidence interval (CI)¼1.50–3.96, Po0.001), and
had a gene dosage effect on melanoma risk in carriers
of multiple variants (OR for one variant: 2.18; 95%
CI¼1.32–3.60, P¼0.002, and OR for X2 variants: 6.97;
95% CI¼1.86–26.12, P¼ 0.004). Subjects carrying the major
function variants and those with minor variants had 4.6 and
2.0 times higher risk respectively of being diagnosed with
melanoma, relative to subjects without variants (Po0.001
and P¼ 0.008, respectively). The variant most strongly
associated with melanoma was the Arg151Cys, with an OR
of 4.18 (95% CI¼1.38–12.7, P¼ 0.012) (Table 2). The
population attributable fraction of melanoma associated
with all non-synonymous MC1R variants was 35% (95%
CI¼18.6–48.0), and 12.7% when taking into account only
the major function alleles.
Stratified analysis of the association between MC1R variants
and the risk of melanoma
We investigated for potential effect modifications of the
association between MC1R variants and melanoma risk by
pigmentation-related variables (Table 5). The risk of mela-
noma was not modified statistically significantly by skin
phototype (P¼0.273), skin color (P¼0.778), eye color
(P¼0.88), or the presence of red hair (P¼0.69).
Association between MC1R variants and age of melanoma
onset, tumor thickness, and tumor location
No statistically significant difference was found between the
MC1R genotype and the age of melanoma diagnosis in our
patients (mean age of diagnosis for MC1R carriers: 52.3 years
and for non-carriers: 52.1 years, P¼ 0.94). With respect to
the anatomic distribution of the tumor, we observed the
highest MC1R allelic frequencies in subjects with tumors
on chronically exposed sites, that is, head and neck (69.6%),
compared to those on intermittently exposed areas, that is,
trunk and extremities (56.8%), and tumors on rarely exposed
sites, that is, soles of feet and nail beds (59.5%). However, no
statistically significant difference was found among the three
groups (P¼0.543). A similar result was found when multiple
(X2) variants were taken into account (data not shown).
Finally, we did not identify any relation between the presence
of MC1R polymorphisms and the Breslow thickness of the
tumor, the distribution of variants being similar in tumors
below and above the median thickness of 2.1 mm
(P¼0.536). In addition, the median thickness of tumors in
Table 2. Non-synonymous MC1R variant alleles identified in cases and controls and their individual association
with melanoma risk1
MC1R variant2 Nucleotide change Cases of CM Controls OR 95% CI P
Wild type 50 (40.6) 95 (62.5) 1 Referent
Val60Leu 178G4T 45 (36.6) 31 (20.0) 2.76 (1.56, 4.88) 0.001
Ser83Pro 247T4C 0 (0.0) 1 (0.7) — — —
Val92Met 274G4A 10 (8.1) 12 (7.9) 1.58 (0.64, 3.92) 0.320
Thr95Met 284C4T 1 (0.8) 1 (0.7) 1.90 (0.12, 31.0) 0.652
Leu106Gln 317T4A 0 (0) 1 (0.7) — — —
Ala111Val 331C4T 0 (0) 2 (1.3) — — —
Arg142His 425G4A 7 (5.7) 2 (1.3) 6.65 (1.33, 33.2) 0.021
Arg151Cys 451C4T 11 (8.9) 5 (3.3) 4.18 (1.38, 12.7) 0.012
Ile155Thr 464C4T 2 (1.6) 0 (0.0) — — —
Arg160Trp 478C4T 5 (4.1) 3 (2.0) 3.17 (0.73, 13.8) 0.125
Arg163Gln 488G4A 2 (1.6) 2 (1.3) 1.90 (0.26, 13.9) 0.527
Lys278Glu 832A4G 1 (0.8) 0 (0) — — —
CI, confidence interval; CM, cutaneous melanoma; MC1R, melanocortin 1 receptor; OR, odds ratio.
1Apart from Thr314Thr, which was frequently found (19.5% in cases and 10.5% in controls), other synonymous MC1R changes identified were Ile63Ile,
Leu93Leu, Gln217Gln, Gly220Gly, and Gln233Gln (o0.5% of total alleles).
2Compound heterozygotes and homozygotes are grouped together as ‘‘MC1R variant’’.
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carriers of the major function alleles was not significantly
different than in those carrying the minor variants (P¼0.502).
DISCUSSION
According to several case–control studies performed in the
British Isles, The Netherlands, and Australia, MC1R is a
highly polymorphic gene in Caucasians, with over 50% of the
control population carrying at least one MC1R variant
(Valverde et al., 1995; Smith et al., 1998; Kennedy et al.,
2001). In our study, the rate of polymorphism in the control
population (37%) was lower to that reported in countries of
northern latitude but also in countries of close geographic
proximity, such as Italy, where allelic frequencies of MC1R
were identified in 58% of the control population (Landi et al.,
2005). This difference may be explained by the higher
proportion of individuals with darker skin complexion in our
study, with over 55% of subjects being characterized as
having skin type III/IV. It could also be attributed to the
different genetic background or ancestry of the Greek
population, which differs from that of populations of Celtic
or Germanic origin. In accordance with studies of southern
European populations (Matichard et al., 2004; Landi et al.,
2005), the frequency of the major function variants was lower
than that reported in more fair-skinned individuals (Palmer
et al., 2000; Kennedy et al., 2001). In addition, we did not
detect the variants Asp84Glu and Asp294His, both of which
have been strongly associated with red hair color, fair skin,
and melanoma (Valverde et al., 1996; Healy et al., 2000;
Palmer et al., 2000; Kennedy et al., 2001). It is possible that
these variants are quite rare in the Greek population and that
our small-sized study was unable to detect them. Their
notable absence, however, in conjunction with the overall
reduced frequency of the major function variants in our
cohort may indicate a different pattern of MC1R diversity in
populations of lower latitudes with high UVR intensity. An
additional finding in favor of this hypothesis is the high
Table 3. Association of MC1R genotype with















Blonde 9 (60.0) 3 (33.3) 1 (6.8)
Red 2 (40.0) 0 (0) 3 (60.0)
Light brown 24 (61.5) 14 (36.0) 1 (2.6)
Dark brown 54 (70.1) 21 (27.7) 2 (2.6)
Black 4 (30.8) 7 (53.8) 2 (15.4)
Eye color 0.956
Blue 17 (68.0) 7 (28.0) 1 (4.0)
Green–light
brown
41 (63.8) 20 (30.8) 4 (6.1)
Dark brown 35 (59.3) 20 (33.9) 4 (6.8)
Skin color 0.297
White 36 (59.0) 19 (31.5) 6 (9.8)
Light brown 44 (64.7) 23 (33.8) 1 (1.5)
Dark brown 13 (65.0) 5 (25.0) 2 (10.0)
Phototype 0.158
Type I 3 (42.8) 2 (28.6) 2 (28.6)
Type II 36 (65.4) 20 (36.6) 1 (1.8)
Type III 34 (61.8) 20 (36.4) 1 (1.8)
Type IV 20 (62.5) 9 (28.1) 3 (9.4)
MC1R, melanocortin 1 receptor.
1Wild-type variants include synonymous variants.
2Major function variants are those that have been shown to cause a
significant impairment of receptor function and are strongly associated
with red hair, fair skin, and skin cancer, that is, Asp84Glu, Arg142His,
Arg151Cys, Arg160Trp, and Asp294His (Wong and Rees, 2005).





N (%) (n=155) OR (95% CI) P
Wild type1 50 (40.6) 95 (62.5) 1.0 (referent)
Any variant 73 (59.4) 57 (37.5) 2.43 (1.50–3.96) o0.001
Minor function variants 51 (41.5) 48 (31.6) 2.02 (1.20–3.40) 0.008
Major function variants2 22 (17.9) 9 (5.9) 4.64 (1.99–10.84) o0.001
Heterozygotes (var/wt) 55 (44.7) 49 (32.2) 2.13 (1.27–3.57) 0.004
Compound heterozygotes and homozygotes (var/var) 18 (4.6) 8 (5.3) 4.28 (1.74–10.52) 0.002
One variant 62 (50.4) 54 (35.5) 2.18 (1.32–3.60) 0.002
X2 variants3 11 (8.9) 3 (2.0) 6.97 (1.86–26.12) 0.004
CI, confidence interval; MC1R, melanocortin 1 receptor; OR, odds ratio.
1Wild-type variants include synonymous variants.
2Major function variants are considered as any of the following: Asp84Glu, Arg142His, Arg151Cys, Arg160Trp, and Asp294His.
3Two or more variants at any codon of the MC1R sequence in the same subject.
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frequency of the silent polymorphism Thr314Thr (10% in
our control subjects), which is frequently found in African
populations (Harding et al., 2000), but rarely in northern
Europeans (Flanagan et al., 2000).
In our study, the presence of MC1R variant alleles was
associated with red hair color, supporting the role of MC1R as
an important determinant of human hair pigmentation
(Naysmith et al., 2004; Rees, 2004). Although the number
of red hairs in our cohort was low, possibly reflecting the low
prevalence of such individuals in the Greek population, it is
interesting that almost half of our red-haired individuals
(three of eight subjects) carried the homozygous wild-type
MC1R alleles, the rest being either simple or compound
heterozygotes for Val60Leu, Arg142His, Arg151Cys, and
Arg160Trp. This finding contrasts the high frequency (480%)
of MC1R mutants in northern European individuals with red
hair, most of them being homozygotes or compound
heterozygotes for two variant MC1R alleles (Flanagan et al.,
2000). As previously suggested, it is possible that MC1R is not
solely responsible for the red hair phenotype and that perhaps
other genetic loci, yet unidentified, contribute to this
phenotypic trait (Box et al., 1997), particularly in our
population.
Our results confirm the relation of MC1R polymorphisms
with the risk of melanoma development, with an OR varying
between 2 and 7, depending on the number of variants
present. Although data comparison among studies is not
always possible, it is interesting, however, that the magnitude
of melanoma risk in individuals with MC1R variants in this
study was similar to that reported in relevant studies in
subjects of Celtic, Germanic, or other Mediterranean origin
(Valverde et al., 1996; Ichii-Jones et al., 1999; Palmer et al.,
2000; Box et al., 2001b; Kennedy et al., 2001; Matichard
et al., 2004; Landi et al., 2005). The presence of multiple
variants more than doubled the risk of melanoma, a finding
that represents a gene dosage effect, similar to that reported
on hair color, skin color (Flanagan et al., 2000), and freckling
(Bastiaens et al., 2001a). There is evidence from functional
studies that compound heterozygotes and homozygotes of
specific MC1R alleles have a much reduced cAMP reponse to
a-melanocyte-stimulating hormone in melanocyte cultures
compared to simple heterozygotes (Scott et al., 2002). A
profoundly impaired receptor function can be, therefore,
postulated in carriers of multiple variants, but additional
molecular events, downstream of MC1R activation, and their
effect on melanoma risk need to be better understood.
Of all individual MC1R variants, only three were found to
be significantly associated with an increased risk of melano-
ma, namely Val60Leu, Arg142His, and Arg151Cys, with the
latter exhibiting the strongest association (OR¼4.18; 95%
Table 5. Association between the presence of MC1R variants and the risk of melanoma according to skin
phototype, eye color, skin color, and presence of red hair
Phenotypic characteristics MC1R status Melanoma Controls P OR P for test of homogeneity of odds
Phototype
I, II wt/v, v/v1 38 (66.7) 23 (37.1) 0.001 3.39 0.273
wt/wt 19 (33.3) 39 (62.9)
III, IV wt/v, v/v 30 (53.6) 33 (37.9) 0.066 1.89
wt/wt 26 (46.4) 54 (62.1)
Eye color
Brown–dark+light wt/v, v/v 37 (58.7) 37 (37.8) 0.009 2.35 0.880
wt/wt 26 (41.3) 61 (62.2)
Grey, green, blue wt/v, v/v 30 (61.2) 19 (37.3) 0.017 2.66
wt/wt 19 (38.8) 32 (62.7)
Skin
White+light brown wt/v, v/v1 66 (60.6) 49 (38.0) 0.001 2.51 0.778
wt/wt 43 (39.5) 80 (62.0)
Dark wt/v, v/v 2 (66.7) 7 (35.0) 0.295 3.71
wt/wt 1 (33.3) 13 (65.0)
Red hair
Yes wt/v, v/v 2 (66.7) 3 (60.0) 0.850 1.33 0.694
wt/wt 1 (33.3) 2 (40.0)
No wt/v, v/v 65 (59.6) 53 (36.8) o0.001 2.54
wt/wt 44 (40.4) 91 (63.2)
MC1R, melanocortin 1 receptor; OR, odds ratio; v/v, homozygotes and compound heterozygotes; wt/v, heterozygotes; wt/wt, wild-type sequence.
1Synonymous variants are included in the group of wild-type homozygotes.
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CI¼1.38–12.7, P¼ 0.012). Arg151Cys has been strongly
linked to melanoma risk in almost all relevant studies, but for
Arg142His, the results are not always consistent (Palmer
et al., 2000; Kennedy et al., 2001). The role of Val60Leu is
also quite controversial, as the magnitude of melanoma risk it
confers varies among studies. Reports from Australia and the
Netherlands have shown a weak association with melanoma
risk (Palmer et al., 2000; Kennedy et al., 2001). In contrast, a
French study demonstrated similar findings to our study, with
Val60Leu being not only the most frequent variant but a
strong predictor of melanoma risk among all other variants
(Matichard et al., 2004). Other variants that have been
previously linked to melanoma risk, such as Val92Met and
Arg160Trp, were not found to have a significant association
with melanoma development in our cohort, possibly owing
to the small size of our effectives.
In concordance with the results of other studies, we did not
find any association of MC1R variants with the age of onset
(Matichard et al., 2004; Landi et al., 2005). Recent evidence
has also suggested a relation between MC1R polymorphisms
and tumor thickness as a measure of tumor progression (Landi
et al., 2005). In this study, we were not able to confirm such
an association. A potential explanation of this discrepancy
could relate to the higher median thickness of tumors in our
series, compared to the study by Landi, where the median
tumor thickness was 1.06 mm. Having a lower percentage of
thin tumors may have prohibited us to reveal a difference
between MC1R carriers and non-carriers with respect to
tumor thickness. Additional studies are required to address
this question, using a larger number of patients and more
precise markers of melanoma progression, that is, presence of
ulceration and number of mitoses.
Our study has certain limitations. Its small size did not
provide us with adequate statistical power in some subgroup
analysis. In addition, the control group was constituted
mainly by outpatients with minor skin problems and may,
therefore, not be representative of the general population.
Other studies, however, have used a similar method of
selection, possibly owing to its practicability in a hospital-
based environment. Measurement of phenotypic variants
may also have carried some bias, as it relied on self-report
of natural hair color, assessment of apparent skin color, and
self-evaluation of the tendency to burn or tan (Rampen
et al., 1988). The Fitzpatrick skin phototype classification
(Fitzpatrick, 1988) is considered a crude measurement of skin
type, but is yet the most commonly used system for this purpose.
It is possible that more accurate measures of melanin concen-
trations, such as spectophotometry of cutaneous melanin
density, may provide a more accurate measure of skin type
and predict more objectively the risk of skin cancer (Dwyer
et al., 2002). In a recent study, the MC1R genotype status
offered a rather modest improvement in the overall prediction
of skin cancer, provided by the spectrophotometric estima-
tion of cutaneous melanin density (Dwyer et al., 2004).
In conclusion, the presence of MC1R variants is a risk
factor of melanoma in a case–control study of a southern
European population. Considering the relatively low inci-
dence of melanoma in this geographical area and the darker
skin complexion of our population, the findings of this study
further strengthen the association between MC1R polymorph-
isms and melanoma risk. The association remained signifi-
cant even after stratification for pigmented characteristics,
suggesting that the effect of MC1R is not solely exerted
through hair or skin color. Further research will shed more
light on the causal pathways through which pigmentation
genes, such as MC1R, contribute to skin cancer risk.
MATERIALS AND METHODS
Study population
The study was part of a multicenter case–control study taking place
from January 2004 to January 2005 at three medical centers in
Athens, namely Andreas Sygros Hospital, Gennimatas General State
Hospital, and Laiko Hospital. The study included 123 cases of non-
familial melanoma (63 male and 60 female subjects) and 155 control
subjects (84 male and 71 female subjects). All cases and controls
were Caucasians, most of whom (98%) originated from central and
southern Greece. Three patients were born in Albania, one in
Ukraine, and one originated from Australia. The control subjects
included outpatients referred to the outpatient dermatology clinics of
A. Sygros Hospital for minor skin problems (70%) and healthy
volunteers from hospital personnel (30%). Individuals with a history
of cutaneous malignancies, immunosuppression, or a genoderma-
tosis predisposing to skin cancer (i.e., xeroderma pigmentosum,
albinism, and Gorlin syndrome) were excluded from the study. The
participation rate was similar in cases and controls (approximately
90%). The study was conducted according to the Declaration of
Helsinki principles for the use of human subjects and was approved
by the Ethics Committee of A. Sygros Hospital. Informed consent was
obtained from the participants.
Collection of data from interview and clinical examination
All subjects underwent a standardized personal interview by trained
interviewers and data were entered in a specially designed interview
sheet. Questions were asked regarding residential history, medical
history, personal or family history of cancer, and exposure to solar
and artificial UVR. Information on skin color (recorded as white,
light brown, and dark), eye color (classified as grey, blue, green, light
brown, and dark brown), and original hair color (red, blonde, light
brown, dark brown, and black) were also recorded. Skin phototype
was assessed according to the Fitpatrick classification (skin type I:
always burns, never tans; type II: always burns, then tans; type III:
always tans, burns sometimes; type IV: always tans, never burns).
Detection of MC1R variants – sequencing
Peripheral blood from patients and controls was collected by
venipuncture in 2 ml EDTA tubes and was processed at the Medical
Genetics Department of the Agia Sophia Hospital for the molecular
part of the study. Genomic DNA extraction was performed using
200ml of whole blood giving a yield of 30 ng/ml DNA, with the
Qiagen Mini Blood DNA kit according to the manufacturer’s
instructions (QIAGEN GmbH, Hilden, Germany). Three pairs of
overlapping primers were designed to amplify the whole coding
sequence of the MC1R gene, a 954 bp, single exon gene (NCBI
access number X65634). These were MCRFrA50 50-agc acc atg aac
taa gca gga ca-30 and MCRFrA30 50-cag gca gca gat gaa gca gta cat-
30, MCRFrB50 50-gcc tgg ggc tgg tga gct tgg tgg a-30 and MCRFrB30 50-
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aca gca cgg cca tga gca cca gca t-30, and MCRFrC50 50-tgg ccg tcc tgc
tgt gcc tcg t-30 and MCRFrC30 50-acc aca ata tca cca cct ccc tct-30.
The three primer pairs give PCR products of 332, 480, and 453 bp,
respectively. PCR products were electrophoresed on 1.5% w/v
agarose gels. All primers were M13 tailed in order to use the
amplicons directly for the subsequent sequencing reaction. The
forward primer M13 tail sequence was 50-gta aaa cga cgg cca-30 and
the reverse 50-cag gaa aca gct atg ac-30. Direct bidirectional
sequencing followed using fluorescently labeled M13-tailed primers
(forward Cy5.0: 50-gta aaa cga cgg cca-30 and reverse Cy5.5: 50-cag
gaa aca gct atg ac-30). The Visible Genetics sequencing kit (Visible
Genetics, Ontario, Canada) was performed on the PCR products. The
sequencing reactions were analyzed on the OpengeneTM auto-
mated sequencing system (Visible Genetics). Sequencing analysis
was carried out automatically and was confirmed manually. The
reactions were carried out at least twice for each sample.
Statistical analysis
In our analysis, the presence of MC1R variants was defined by the
presence of non-synonymous variants, which lead to a change of
amino acid. We investigated the impact of each MC1R variant on
melanoma risk separately as well as by combining all different
variants. More specifically, in the latter approach, we considered (a)
the presence or absence of MC1R variants and (b) the presence of
major function variants, the presence of minor function variants, and
the absence of variants. The major function variant group included
those variants that have been shown to cause a significant impairment
of receptor function and are strongly associated with red hair, fair
skin, and skin cancer, that is, Asp84Glu, Arg151Cys, Arg160Trp, and
Asp294His (Wong and Rees, 2005). All remaining non-synonymous
variants were considered as minor function variants. The w2 test was
used to test whether the two groups of melanoma cases and control
subjects differed in terms of demographic/phenotypic characteristics
and of MC1R gene variants frequencies. Crude ORs along with 95%
CIs were calculated in order to estimate the risk of melanoma among
patients with MC1R variants relative to wild-type homozygotes. We
also explored potential effect modifications of the association
between MC1R genotypes and melanoma risk by stratifying accord-
ing to potential confounding factors, that is, skin phototype, hair
color, eye color, and skin color. The test for homogeneity of odds was
applied for the stratified analysis.
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